Immunotherapy Works Effectively on Stage 2 and 3 Cancers
Dear Friend,
Immunotherapy drugs have become a valuable weapon in the fight against metastatic cancer, also known as Stage 4 cancer. Researchers are discovering that immunotherapy for cancer treatment can also have positive results when used during stages two and three of the disease.
Immunotherapy and Early-Stage Cancer
At the recent European Society for Medical Oncology (ESMO) congress in Madrid, one pharmaceutical company presented successful trial results for its immuno-oncology drug in treating mid-stage lung cancer. The manufacturer, AstraZeneca, is considered a latecomer to the I-O (Immuno-Oncology) field as compared to other more established companies.
For their part, Bristol-Meyers produced evidence regarding Opdivo, the company's widely used late-stage Immuno-Oncology drug. Opdivo has been shown to prevent relapses in melanoma patients when administered immediately post-surgery.
Supplementing Surgery with Immunotherapy
This method of following surgery with cancer treatment is referred to as adjuvant therapy. With the success of Opdivo, a number of trials are being conducted on adjuvant therapy using Immuno-Oncology drugs with a range of cancer types. Some trials are even focusing on neoadjuvant, or pre-surgery, treatment for breast, neck, and head cancers.
What's Next in the World of Immuno-Oncology?
If the trend of early-stage immunotherapy treatment continues, early detection becomes even more important than ever. According to Pascal Soriot, CEO of AstraZeneca, effective early treatment is a powerful incentive for increased use of screening methods.
Non-Toxic Immunotherapy Programs from Issels®
Our cancer vaccines and other non-toxic, personally tailored immunotherapy treatment programs have resulted in long-term remission for patients with all types of therapy-resistant cancers. Contact us for more information about Issels®, the leader in non-toxic immunotherapy for cancer treatment.
|